What You Should Know
The Deal: Sensei Biotherapeutics has acquired Faeth Therapeutics in a stock-for-stock transaction. Concurrently, Sensei raised a massive $200M in private placement financing to fuel the combined company.The Asset: The centerpiece of the deal is PIKTOR, an oral drug combination that targets the PI3K/AKT/mTOR pathway. Unlike previous drugs that hit just one "node," PIKTOR hits multiple nodes simultaneously to prevent the tumor from finding a workaround.The Promise: In early
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Merck to Leverage Mayo Clinic Platform_Orchestrate for AI-Enabled Drug Discovery
What You Should Know
The Deal: Merck and Mayo Clinic have signed a strategic research agreement to apply AI and multimodal data to drug discovery. This is Mayo Clinic's first collaboration of this scale with a global biopharma company.The Data: Merck gains access to Mayo Clinic Platform_Orchestrate, a treasure trove of de-identified clinical data, genomic datasets, lab results, imaging, and clinical notes from the world's top-ranked hospital system.The Focus: The partnership will initially
Read More
The “Pilot Purgatory”: Why 80% of Pharma AI Projects Fail (And How to Fix It)
Artificial intelligence is rapidly reshaping the life sciences industry, influencing everything from early-stage drug discovery to clinical operations, manufacturing, and patient engagement. While enthusiasm for AI remains strong, many organizations continue to struggle with moving from experimentation to scalable, enterprise-ready deployment. Recent industry data found that 80% of healthcare AI projects fail to scale beyond the pilot phase. In highly regulated environments like healthcare, AI
Read More
Mayo Clinic Platform Standardizes Cancer Data to Speed Up Trials
Mayo Clinic Platform Standardizes Cancer Data to Speed Up Trials
What You Should Know
The Upgrade: Mayo Clinic Platform_Orchestrate has launched new capabilities that allow researchers to access standardized, "research-ready" cancer data.The Standard: The platform now utilizes the OMOP Oncology framework, which structures complex, messy data (like pathology reports and tumor staging) into a consistent format that algorithms can easily analyze.The Future: Later this year, Mayo will
Read More
How Agentic AI Optimizes HCP Marketing and ROI in Life Sciences
Most life sciences companies may know more about their healthcare professionals (HCPs) than they realize, but too often they can’t use that data when it matters. For example, an HCP may have just attended a conference where a competitor showcased their drug’s promising results, published research, and shifted their prescriptions to a rival product in the past quarter. In most companies, legacy IT infrastructure and data silos keep this information in disparate systems across CRM, events
Read More
Opentrons and NVIDIA Partner to Develop Physical AI for Laboratory Robotics
What You Should Know
The Partnership: Opentrons Labworks, the company behind the ubiquitous pipette robots found in labs worldwide, is partnering with NVIDIA to accelerate the development of "Physical AI."The Integration: By combining NVIDIA's Isaac and Cosmos platforms with Opentrons' fleet of 10,000+ robots, the companies aim to create a "closed loop" where AI doesn't just predict drug targets (via NVIDIA BioNeMo) but physically validates them in the wet lab.The Goal: The collaboration
Read More
From Mass Messaging to N-of-1: How Agentic AI Closes the Life Sciences Trust Gap
What You Should Know
The Failure: Lirio, in partnership with healthcare consultancy Sage Growth Partners, released "From Mass Messaging to N-of-1," a survey of 75 life sciences executives. The report reveals that traditional "segment-based" personalization in life sciences is failing to move the needle. 79% of leaders cite clinical trial engagement and 72% cite medication adherence as their most persistent challenges.The Shift: The industry is pivoting from "Mass Messaging" to "N-of-1"
Read More
Why Pharma Marketing’s “Safe” Playbook Is Expiring in 2026
Pharma marketing has always operated within strict regulatory boundaries. What’s changing as we head into 2026 is not just the level of scrutiny, but the pace and unpredictability of it. Platform policies, data usage rules, targeting limitations, and compliance standards are evolving unevenly across channels and often without much warning.
That volatility is forcing pharma marketers to rethink how they plan, buy, and optimize media. The old playbook which was built around a
Read More
ConcertAI Bets “Agentic AI” Can Fix the Broken Clinical Trial Timeline
What You Should Know
The Launch: ConcertAI has released Accelerated Clinical Trials (ACT), an enterprise platform designed to automate the clinical trial lifecycle using "Agentic AI"—autonomous software that performs tasks rather than just generating text.The Promise: By integrating proprietary Real-World Data (RWD) with AI workflows, the platform claims it can shorten trial timelines by 10 to 20 months and reduce costly protocol amendments by 50%.The Tech: Built on the CARAai™
Read More
Medable Deploys ”Agentic AI” to Rescue Overwhelmed Investigators
What You Should Know:
- Medable Inc., the leading technology platform for AI-powered clinical development, today launched Agentic AI for research sites to reduce burden and assist principal investigators (PIs) in oversight and monitoring of electronic clinical outcome assessment (eCOA) data.
- Medable’s newest agent integrates seamlessly within its eCOA system workflows. Released just after Medable’s TMF and CRA agents, its PI Summary Agent continues the company’s rapid rollout of
Read More
